SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-048476
Filing Date
2020-04-20
Accepted
2020-04-20 08:00:42
Documents
6
Period of Report
2020-05-29
Effectiveness Date
2020-04-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm202063-2_def14a.htm DEF 14A 1391952
2 GRAPHIC lg_adaptimmune-4clr.jpg GRAPHIC 13939
3 GRAPHIC tm202063d2-lc_perform4clr.jpg GRAPHIC 2484066
4 GRAPHIC tm202063d2-bc_chief4clr.jpg GRAPHIC 40831
5 GRAPHIC tm202063d2-icon_comsharbwlr.jpg GRAPHIC 3687
6 GRAPHIC tm202063d2-icon_computbwlr.jpg GRAPHIC 2862
  Complete submission text file 0001104659-20-048476.txt   4899227
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37368 | Film No.: 20801280
SIC: 2836 Biological Products, (No Diagnostic Substances)